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Lgr5 marks resident adult epithelial stem cells at the gland base in the mouse pyloric 36 
stomach1, but the identity of the equivalent human stem cell population remains elusive 37 
due to a lack of surface markers facilitating its prospective isolation and validation. 38 
Lgr5+ intestinal stem cells are major sources of cancer following Wnt pathway 39 
hyperactivation in mice2. However, the contribution of pyloric Lgr5+ stem cells to 40 
gastric cancer following Wnt pathway dysregulation, a frequent event in human gastric 41 
cancer3, is unknown. Here, we employed comparative profiling of Lgr5+ stem cell 42 
populations along the mouse gastrointestinal tract to identify, then functionally validate 43 
the membrane protein AQP5 as a marker that enriches for mouse and human adult 44 
pyloric stem cells. We show that stem cells within the Aqp5+ compartment are a source 45 
of Wnt-driven, invasive gastric cancer in vivo using new Aqp5-CreERT2 mouse models. 46 
Additionally, tumour-resident Aqp5+ cells can selectively initiate organoid growth in 47 
vitro, indicating that this population harbours potential cancer stem cells. In human 48 
gastric cancer, AQP5 is robustly expressed in primary and metastases of intestinal and 49 
diffuse subtypes, often displaying altered cellular localization compared to healthy 50 
tissue. These new markers and mouse models will be an invaluable resource for 51 
deciphering early gastric cancer formation and for isolating and characterizing human 52 
stomach stem cells as a prerequisite to potentially harnessing their regenerative 53 
medicine potential in the clinic. 54 
Comparative profiling yields new markers 55 
To identify markers specific to Lgr5Hi pyloric stem cells within the gastrointestinal tract, we 56 
profiled the transcriptomes of qPCR-validated Lgr5-EGFPHi (Lgr5+ stem cells), Lgr5-EGFPLo 57 
(immediate progeny) and unfractionated populations from the small intestine, colon, gastric 58 
pylorus of Lgr5-EGFP-IRES-CreERT2 mice4 by microarray, and identified genes selectively 59 
enriched in Lgr5Hi pyloric stem cells (Fig. 1a; Extended Data Fig. 1a-d, Supplementary Table 60 
1). This dataset also revealed the transcriptional signature of Lgr5Hi colon stem cells 61 
(Supplementary Table 2). Profiling of Lgr5-EGFPHi, Lgr5-EGFPLo and Lgr5-EGFPNeg pylorus 62 
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populations from another Lgr5-reporter model, Lgr5-DTR-EGFP5, revealed  67 overlapping 63 
genes (Fig. 1b).  64 
Candidate markers were empirically validated by qPCR, in situ hybridization (ISH) and 65 
immunostaining. Optimal candidates presented enriched expression in the Lgr5-EGFPHi 66 
pyloric population by qPCR, robust, localized mRNA/protein expression within the Lgr5+ 67 
pyloric gland base1, minimal expression in intestines and gastric corpus and co-expression 68 
with Lgr5 (Extended Data Fig. 1j-n). Six candidates were selected: Alpha-1,4-N-69 
Acetylglucosaminyltransferase (A4gnt), Aquaporin-5 (Aqp5), Gastric intrinsic factor (Gif), 70 
Mucin6 (Muc6), Solute carrier protein 9a3 (Slc9a3/Nhe3) and Secreted phosphoprotein 1 71 
(Spp1/Osteopontin) (Fig. 1c-m; Extended Data Fig. 1e-n, Supplementary Table 3).   72 
To validate the six candidates as markers of pyloric stem cell-enriched populations, we 73 
generated EGFP-IRES-CreERT2 mouse models for Aqp5, A4gnt, Spp1 and Slc9A3 74 
(Extended Data Fig. 2a), and Aqp5-2A-EGFP, Slc9A3-2A-EGFP, Aqp-2A-CreERT2 and 75 
Slc9A3-2A-CreERT2 mice in which endogenous gene expression is unaffected (Extended 76 
Data Fig. 2b). GFP expression in the pylori of the 2A-EGFP models recapitulated endogenous 77 
gene expression in the pylorus and small intestine (Extended Data Fig. 2c-f). Additionally, 78 
97.4% concurrence between the Aqp5+ and Slc9a3+ pyloric populations by co-staining 79 
(Extended Data Fig. 2g-h) reaffirms that they effectively label the same population. 80 
The in vivo contribution of the gland populations expressing the candidate genes to epithelial 81 
renewal was evaluated via lineage tracing in CreERT2;Rosa26-tdTomatoLSL lines. tdTomato 82 
(dTom) expression was first observed at the gland bases in all lines 20-48 hours post-83 
Tamoxifen induction, confirming the expected Cre expression domain (Extended Data Fig. 3a-84 
d, q-r). After several months (tissue turnover spans 7-10 days1), multiple entirely dTom+ 85 
glands were evident throughout the pylorus, documenting the long-term self-renewal and 86 
multipotency of the cells expressing Aqp5, Slc9A3, Spp1 or A4gnt (Extended Data Fig. 3e-h, 87 
s-t). Importantly, no intestinal tracing was observed, except for transient reporter expression 88 
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within the villi of Slc9A3-Cre models (Extended Data Fig. 2f, 3i-x). These observations confirm 89 
that populations expressing Aqp5, Spp1, Slc9a3 and A4gnt contain pyloric stem cells. 90 
 91 
Aqp5 enriches for stem cells in mice 92 
Aqp5 water channel protein6 emerged as a promising candidate for isolating pyloric stem cells 93 
from mice and humans. EGFP expression was restricted to pyloric gland bases in Aqp5-94 
EGFP-IRES-CreERT2 and Aqp5-2A-EGFP mouse models (Extended Data Fig. 2c,w). Sorted 95 
EGFP+ cells from adult Aqp5-EGFP-IRES-CreERT2 mice (Fig. 2a) showed a 9-fold and 15-96 
fold enrichment of Aqp5 and Lgr5 transcripts respectively over EGFP- cells (Extended Data 97 
Fig. 2u-v). By immunostaining, endogenous Aqp5 protein co-localized with EGFP (Extended 98 
Data Fig. 2w). Thus, the Aqp5 models faithfully report Aqp5 expression in pyloric gland bases.  99 
Next, we found that Aqp5+ population overlapped with Gif and Ki67 but not Gastrin (Gast), 100 
Chromogranin A (Chga) or Mucin5ac (Muc5ac), whilst the Lgr5-EGFPHi population expressed 101 
major gastric lineage markers (Gif, Gast, Chga) and Ki67 (Fig. 2b-e, Extended Data Fig. 2k-102 
m, x). This observation was confirmed via single-cell analysis of Lgr5-EGFPHi pyloric stem 103 
cells by CEL-Seq/RaceID7. The Lgr5-EGFPHi compartment comprised three subpopulations: 104 
the major subpopulation co-expressed some of the new pyloric markers – Aqp5, Gif and Muc6 105 
(Extended Data Fig. 2n-q), while the two minor subpopulations expressed Chga/Gast and 106 
Krt8/Krt18 (Extended Data Fig. 2r-s). Proliferation marker expression was significantly 107 
enriched in the major subpopulation (Extended Data Fig. 2t). Aqp5 staining on Lgr5-DTR-108 
EGFP pylori revealed 94.1% overlap between the two populations (Extended Data Fig. 2i-j), 109 
underscoring the CEL-Seq finding that Aqp5 marks the major subpopulation of Lgr5Hi cells.  110 
Lineage tracing using adult Aqp5-EGFP-IRES-CreERT2;Rosa26-tdTomatoLSL (Aqp5-IRES-111 
CreERT2;dTom) mice detailed the homeostatic behaviour of Aqp5+ cells – dTom+ cells  112 
appeared exclusively at the gland bases 20 hours post-tamoxifen induction (Fig. 2f, Extended 113 
Data Fig. 3y), expanded to clones reaching gland surfaces by 5 days (Fig. 2g), and persisted 114 
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for 1 year, demonstrating self-renewal of Aqp5+ cells (Fig. 2h-i, Extended Data Fig. 3z,c’). 115 
Uninduced controls presented negligible dTom+ clones (Extended Data Fig. 3a’-b’). Six 116 
months post-induction, dTom+ clones comprised the major pyloric lineages expressing Gif, 117 
Gast, Chga and Muc5ac (Fig. 3j-m), confirming multipotency in the Aqp5+ population. Ablating 118 
endogenous Aqp5+ cells using a new Aqp5-2A-DTR model severely disrupted the gland 119 
bases (Extended Data Fig. 4k-r).  120 
Tracing was absent from corpus, small intestine and colon, except for Brunner’s glands 121 
(Extended Data Fig. 3d’-h’). Our Aqp5-2A-EGFP and Aqp5-CreERT2 models also faithfully 122 
reported endogenous Aqp5 expression in tissues such as cornea, lung, mammary gland and 123 
salivary gland13,14 (data not shown). 124 
To evaluate Aqp5’s utility as a marker for isolating enriched pyloric stem cell populations, we 125 
sorted Aqp5+ and Aqp5- cells from adult wild-type mice using anti-Aqp5 antibody (Fig. 2n, 126 
Extended Data Fig. 4a-b) to profile their transcriptomes and evaluate their in vitro organoid-127 
forming capacity. Aqp5 and Lgr5 were markedly enriched in Aqp5+ population relative to 128 
Aqp5- population by qPCR and microarray (Fig. 2o-p, Extended Data Fig. 4d-e). Aqp5+ and 129 
Lgr5-EGFPHi transcriptomes are highly correlated by GSEA analysis (FDR p-value<0.001, 130 
Extended Data Fig. 4c), with the Aqp5+ population presenting strong enrichment of our new 131 
markers (Fig. 2q; Extended Data Fig. 4f) and published gland base markers, Lrig18 and 132 
Runx19 (Extended Data Fig. 4g). Axin210, Cck2r11 and Sox212 were not enriched in the Aqp5+ 133 
population, consistent with their relatively broad expression within pyloric glands (Extended 134 
Data Fig. 4g). Concurring with immunostaining, Aqp5+ cells presented high Gif, moderate 135 
Ki67 and no Muc5ac expression; there was no significant difference in Gast and Chga 136 
expression between Aqp5+ and Aqp5- populations, likely reflecting the limited numbers of 137 
Gastrin+ G cells and Chga+ endocrine cells within the Aqp5- population (Extended Data Fig. 138 
4h). Therefore, this antibody-based strategy facilitates enrichment of mouse pyloric stem cells, 139 
independent of fluorescent reporters. 140 
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Compared to Aqp5- cells, Aqp5+ cells generated three-fold more organoids (0.64% vs 2.58% 141 
respectively) that could be maintained long-term, while the few organoids derived from Aqp5- 142 
cells died within 3 weeks (Fig. 2r-t). Organoid initiation frequencies from Aqp5+ cells (2.58%) 143 
and Lgr5-EGFP+ cells (3.09%) from Lgr5-2A-EGFP mice were similar (Extended Data Fig. 144 
4s-u), indicating high functional overlap. Aqp5+ cell-derived organoids showed heterogeneous 145 
Aqp5 expression, which partially overlapped with Ki67 (Extended Data Fig. 4i-j), similar to its 146 
in vivo pattern. Withdrawal of WNT3A, FGF10 and NOGGIN (Fig. 2u) resulted in 147 
downregulation of stem cell markers Lgr5, Aqp5 and upregulation of differentiation marker 148 
Muc5ac in the organoids after 3 days (Fig. 2v-x). Therefore, Aqp5 is a useful marker for the 149 
prospective isolation of enriched murine pyloric stem cells.  150 
 151 
AQP5 enriches for stem cells in humans 152 
We sought to evaluate AQP5 as a marker facilitating enrichment of human pyloric stem cells. 153 
AQP5 was exclusively expressed at human pyloric gland bases, overlapping with LGR5 and 154 
other mouse pyloric markers, MUC6, A4GNT and SLC9A3 (Fig. 3a-d, Extended Data Fig. 5a-155 
f’). A minor proportion of the human AQP5+ cells were KI67+ (Fig. 3e-f), reminiscent of the 156 
murine pylorus (Extended Data Fig. 2x). Human AQP5+ cells overlapped with PEPC+ and 157 
MUC6+ populations, but, not GIF+ parietal cells or MUC5AC+ foveolar cells (Extended Data 158 
Fig. 5g-j).  159 
We next sorted AQP5+ cells from healthy human pyloric specimens using anti-AQP5 antibody 160 
and verified 10.2-fold enriched AQP5 expression in AQP5+ cells by qPCR (Fig. 3g-h). AQP5+ 161 
cells routinely established organoids that were passaged for >3 months, whereas AQP5- cells 162 
never initiated organoids (Fig. 3i-j). The human pyloric organoids expressed AQP5 163 
heterogeneously, partially overlapping with KI67 (Extended Data Fig. 5k-l). Withdrawal of 164 
WNT3A, NOGGIN and FGF10 resulted in reduced LGR5 and AXIN2, and elevated MUC5AC 165 
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and TFF2 expression, indicating differentiation towards mucous lineages (Fig. 3k-l, Extended 166 
Data Fig. 5m-o).  167 
RNASEQ was then performed on FACS-isolated AQP5+ pyloric cells from healthy human 168 
pylori, and the top hits validated by qPCR. We identified >500 differentially expressed genes 169 
that were significantly up/down-regulated by >4-fold in AQP5+ versus AQP5- populations (Fig. 170 
3m, top candidates in Supplementary Table 3). Q-PCR analysis validated 18 candidates as 171 
being enriched in the AQP5+ population (Extended Data Fig. 6a-e). Selected murine pyloric 172 
stem cell markers, including AQP5, A4GNT and MUC6, and an intestinal stem cell marker, 173 
SMOC215, were upregulated in the AQP5+ fraction by RNASEQ and qPCR (Extended Data 174 
Fig. 6a). ISH confirmed SMOC2 as being expressed in a subset of gland base cells (Extended 175 
Data Fig. 6f-f”). Gene Onotology analysis revealed that approximately half of the candidates 176 
were membrane expressed and had protein-binding activity (Fig. 3n, Extended Data Fig. 6b), 177 
suggesting that additional markers could be identified from our list to potentially further enrich 178 
for pyloric stem cells. Moreover, components of key signalling pathways (e.g. Wnt and Notch), 179 
chemokine signalling and extracellular matrix, and some uncharacterized genes, were also 180 
enriched in the AQP5+ population, highlighting the additional biological insight to be gained 181 
from the profile (Fig. 3n; Extended Data Fig. 6c-g). 182 
Collectively, these data demonstrate AQP5’s utility as a marker for isolating enriched 183 
populations of endogenous stem cells from human stomach epithelia for downstream 184 
purposes.  185 
 186 
Aqp5+ cells as source of gastric cancer 187 
We targeted conditional oncogenic mutations to pyloric stem cell-enriched populations using 188 
our new CreERT2 mouse models to evaluate their contribution to gastric cancer and 189 
circumvent the rapid lethality of Lgr5+ cell-driven cancer models2. To determine how often 190 
pathways are co-dysregulated in gastric cancer, we analysed transcriptomes of gastric cancer 191 
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patients from TCGA (n=155) and East Asian cohorts (n=42) for Wnt/b-catenin, PI3K and Ras 192 
signalling activities (Extended Data Fig. 7a-b), whose components are frequently mutated in 193 
gastric cancer3,16. Using published gene signatures17–19, we found that Wnt/b-catenin 194 
signalling was commonly hyper-activated in human gastric cancer (>80% in both patient 195 
cohorts), and frequently co-occurred with hyper-activation of PI3K and/or Ras signalling (57.1-196 
64.3%)(Extended Data Fig. 7). We thus recapitulated these co-dysregulated pathways by 197 
crossing our pyloric CreERT2 drivers to conditional APC, PTEN and KrasG12D alleles and 198 
induced hyper-activation of the pathways at adulthood.   199 
 200 
All mouse models developed sizeable tumours exclusively in the pylorus, with latencies 201 
ranging from 1-11 months post-induction (n=30/34, Extended Data Fig. 8a-g). In the tumours, 202 
which were classified as tubular-type gastric adenocarcinomas (WHO), malignant structures 203 
surrounded by stroma and inflammatory cells replaced normal glands. Sole hyper-activation 204 
of KrasG12D did not produce pyloric tumours (Extended Data Fig. 8h-i). Pylori of uninduced 205 
mice of the same cancer genotype lacking Cre were normal (Extended Data Fig. 8j).  206 
Across all oncogene combinations, the tumor incidence in 2A-CreERT2 models was 100% 207 
compared to 82.6% in IRES-CreERT2 models (Fig. 4a), reflecting differences in Cre activation 208 
efficacies. The 2A-CreERT2 models displayed almost contiguous tumour growth, contrasting 209 
the multi-focal lesions in IRES-CreERT2 models (Extended Data Fig. 8b-g). Hyper-activation 210 
of Wnt/b-catenin signalling alone [APCfl/fl (A)] was sufficient to drive tumourigenesis, and co-211 
activation of PI3K and/or Kras pathways [APCfl/fl;PTENfl/fl (AP); APCfl/fl;PTENfl/fl; KrasG12D 212 
(APK)]  accelerated tumour development and progression (Extended Data Fig. 8a-g). We also 213 
observed focal invasions through the muscularis mucosae in A and AP models (IRES-214 
CreERT2: 15.8%, 2A-CreERT2: 66.7%; Fig. 4a). As expected, intestinal tumors were never 215 
observed (Extended Data Fig. 8k-l). 216 
We characterized all tumours to detail pathway activation, proliferation status, lineage marker 217 
expression and epithelia/stroma constitution. As there is no major phenotypic differences 218 
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between the different models, we present data from Aqp5-IRES-CreERT2;APK tumours, and 219 
focal invasions from Slc9a3-2A-CreERT2;AP tumours (Fig. 4b-c, i). The pyloric tumours and 220 
focal invasions were predominantly dTom+, confirming Aqp5+ or Slc9A3+ cells as their origins 221 
(Extended Data Fig. 9b, j). In contrast to the normal pylorus (Extended Data Fig. 9p-w), the 222 
gastric adenocarcinomas presented hyper-activation of Wnt/ß-catenin, MAP kinase and 223 
phospho-AKT pathways, evidenced by elevated levels of nuclear/cytoplasmic ß-catenin, 224 
MAPK and phospho-AKT expression respectively (Fig. 4f-h, m-o; Extended Data Fig. 9a). 225 
These regions were also highly proliferative, lacked Gif, Gast and Muc5ac expression 226 
(Extended Data Fig. 9d-g, l-o). In the Aqp5-IRES-CreERT;APK model, dTom+ cells that 227 
retained E-cadherin expression were also found throughout the tumour stroma (Fig. 4e). In 228 
the Slc9a3-2A-CreERT2;AP model, E-cadherin+ cells infiltrated through the muscularis 229 
mucosae (Fig. 4l). Immunostaining for Aqp5-GFP reporter expression revealed Aqp5 230 
expression in a subpopulation of the pyloric tumours, some of which were Ki67+ (Fig. 4d, k, 231 
p). Many of the Aqp5+ cells in the tumours co-expressed Lgr5, with elevated Aqp5 expression 232 
in tumours compared to adjacent normal mucosa (Extended Data Fig. 9h-h”). There was a 233 
low incidence of tumours within non-gastrointestinal organs, such as the salivary gland (<25% 234 
in Aqp5-IRES-CreERT2-driven cancer models), which did not impact survival to preclude 235 
gastric adenocarcinoma development (Extended Data Fig. 9i-i’). Thus, our mouse models 236 
support pyloric stem cell-enriched populations as being a source of invasive, Wnt-driven 237 
gastric cancer and are valuable for modelling gastric cancer in vivo. 238 
 239 
Aqp5+ tumour cells display ex vivo stemness 240 
We then determined if Aqp5+ tumour cells behave differently from their Aqp5- counterparts. 241 
After confirming that the Aqp5-GFP reporter recapitulated endogenous Aqp5 expression in 242 
the tumours (Extended Data Fig. 9x-x’), we cultured sorted Aqp5-GFP+ and GFP- cells 243 
(Extended Data Fig. 9y-z”). Aqp5-GFP+ tumour cells reproducibly generated organoids that 244 
could be serially propagated in the absence of exogenous growth factors, while Aqp5-GFP- 245 
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tumour populations never produced organoids, despite containing Ki67+ cells (Fig. 4p-s). 246 
Moreover, though Aqp5-GFP+ normal cells could initiate organoids with growth factors, they 247 
died upon growth factor removal (Fig. 4r-s). These data suggest that the stem potential of the 248 
tumour is found within the Aqp5+ compartment. 249 
 250 
AQP5 expression in human gastric cancer 251 
We surveyed AQP5 expression in human gastric cancer by immunostaining on a tissue 252 
microarray of 145 distal gastric cancer samples comprising intestinal, diffuse and mixed 253 
subtypes with variable grades of differentiation. AQP5 was expressed in most intestinal, 254 
diffuse and mixed cases (Extended Data Fig. 10a-e). Contrasting normal pylorus, 96.1% of 255 
the tumour samples displayed cytoplasmic AQP5 expression, 37.9%, 3.9% and 37.9% had 256 
membranous, nuclear and multiple localizations of AQP5 respectively (Extended Data Fig. 257 
10a-e). While intracellular AQP5 localization has been reported in other cancers20–22, its 258 
functional significance is unknown.  259 
In full sections of 54 advanced human distal gastric adenocarcinomas and 12 metastatic 260 
lesions, most expressed AQP5 (Extended Data Fig. 10f). Cytoplasmic AQP5 was observed in 261 
all AQP5+ samples, while membranous/luminal, nuclear and multiple sites of AQP5 262 
localization were found in 53.7%, 9.8% and 53.7% of the samples respectively (Extended Data 263 
Fig. 10f-j). In 67.7% of the sections, submucosal malignant cells expressed more AQP5 than 264 
their mucosal counterparts (Extended Data Fig. 10g-j, o, p). AQP5 was expressed in poorly 265 
cohesive tumour cells in 70% of the cohort (Extended Data Fig. 10j, o). All AQP5+ cells in the 266 
submucosa retained E-Cadherin expression, and a subset co-expressed KI67 (Extended Data 267 
Fig. 10k-n). 46.2% of intestinal metaplasia cases, which is strongly correlated with gastric 268 
cancer23,24, displayed mild to moderate AQP5 expression (Extended Data Fig. 10o, q). AQP5 269 
was also weakly expressed in a subset of signet ring cells in 66.7% of the samples (Extended 270 
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Data Fig. 10o, r). 83.3% of the metastatic lesions with AQP5+ primary tumours harboured 271 
AQP5+ tumour cells in the lymph node (Extended Data Fig. 10o, s). 272 
Our broad survey shows that AQP5 is commonly expressed in primary and metastases of 273 
intestinal and diffuse subtypes of gastric cancer.  274 
 275 
Efforts to exploit the therapeutic potential of stem cells require functionally validated markers 276 
for their prospective isolation. For the first time, we purify enriched populations of human 277 
pyloric stem cells and demonstrate the direct contribution of murine Aqp5+ cells to gastric 278 
carcinogenesis. Though the expression of secretory markers like Gif and Muc6 may not 279 
conform to the classical “undifferentiated” stem cell dogma, it is well established in liver and 280 
lung that more specialized cells can serve as homeostatic stem cells25–28, an emerging trend 281 
in epithelial organs29. While Aqp5 is known for regulating water transport in healthy tissues6, 282 
it is increasingly implicated in cancers as a driver of proliferation and invasiveness in vitro30–283 
34. Various human cancers, including gastric, breast, soft tissue sarcoma, lung, oesophageal 284 
and colorectal cancers, present high AQP5 expression21,22,33,35–37. We show that AQP5 is 285 
expressed in most human primary tumours and metastases of intestinal and diffuse gastric 286 
cancer subtypes. Interestingly, we found that tumour-resident Aqp5+ cells in our gastric cancer 287 
mouse model selectively exhibited ex vivo stem potential, indicating that the Aqp5+ tumour 288 
population harbours cancer stem cells. Future evaluation of the stem potential of AQP5+ in 289 
human gastric cancers using our new antibody-based isolation protocols will potentially reveal 290 
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Figure legends 382 
 383 
Fig. 1: Comparative profiling of Lgr5 populations in gastrointestinal tissues yields new pyloric 384 
specific markers 385 
(a) Heatmap of transcriptomes of Lgr5-EGFPHi, Lgr5-EGFPLo and unsorted populations from 386 
mouse pylorus, small intestine and colon (n=4, 2, 3, biological replicates respectively) from 387 
Lgr5-EGFP-IRES-CreERT2 mice. Candidates are enriched only in pylorus-GFPHi population 388 
(black box). 389 
(b) Overlap of candidate markers from Lgr5-EGFP-IRES-CreERT2 (above) and Lgr5-DTR-390 
EGFP (n=4 biological replicates) models (statistical significance assessed by hypergeometric 391 
distribution). 392 
(c) Shortlisted pylorus-specific markers. 393 
(d) Relative Aqp5 expression (qPCR) in gastrointestinal populations (n=2 technical replicates 394 
of pooled sample from 8 mice, means represented).  395 
(e-j) In situ hybridization (ISH) expression of candidate markers in pylorus (n=3 mice). 396 
(k-m) Aqp5 expression with Lgr5 in pylorus by immunostaining (k,m) and ISH (l) (n=3 mice). 397 
Scale bars represent 25 µm.  398 
 399 
Fig. 2: Pyloric Aqp5+ population contains stem cells in vivo 400 
(a) Aqp5-EGFP-IRES-CreERT2 transgene. 401 
(b-e) EGFP co-immunostaining in Aqp5-EGFP-IRES-CreERT2 pylorus with Gif (b), Gastrin 402 
(c), Mucin5ac (d) and Chromogranin A (ChgA, e) (n=3 mice). 403 
(f-i) Lineage tracing of Aqp5-EGFP-IRES-CreERT2;tdTomatoLSL pylori at 20 hours (f), 5 days 404 
(g), 1 month (h) and 6 months (i) (n=3 mice).  405 
(j-m) Co-immunostaining of tdTomato with ChgA (j), Gastrin (k), GIF (l) and Mucin5ac (m) (n=3 406 
mice per marker).  407 
(n) FACS gating for sorting Aqp5+ and Aqp5- cells (means±s.e.m.; n=6 biological replicates). 408 
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(o-p) Relative Aqp5 (o) and Lgr5 (p) expression (qPCR) in sorted populations (means± s.e.m.; 409 
n=10 biological replicates).  410 
(q) Lgr5 and candidate marker enrichment in volcano plot of differentially expressed genes in 411 
Aqp5+ population by microarray (n=4 biological replicates, p-value from one-way ANOVA in 412 
Partek Analysis Software).  413 
(r-s) Outgrowth efficiency of single antibody-mediated FACS-sorted Aqp5+ and Aqp5- cells (r) 414 
with representative images (s) (n=5 biological replicates).  415 
(t) Longevity and highest passage number of organoids from Aqp5+ and Aqp5- cells (n=3 416 
biological replicates). 417 
(u) Organoid differentiation protocol. 418 
(v-x) Relative Aqp5 (v), Lgr5 (w) and Muc5ac (x) expression (qPCR) in Aqp5+ cell-derived 419 
organoids on day 4 of differentiation (n=5 biological replicates). 420 
Scale bars represent 25 µm in (b-m), and 100 µm in (s). Graphs represent means±s.e.m. with 421 
two-sided t-test (r), (t), (v-x).   422 
 423 
Fig. 3: Human pyloric AQP5+ cells are stem cells ex vivo 424 
(a) Immunostaining of AQP5 in normal human pylorus (n=3 biological replicates). 425 
(b-d) AQP5 and LGR5 expression in pylorus (b) near gland surface (c) and base (d) by ISH 426 
(n=3 biological replicates). 427 
(e-f) AQP5 and KI67 co-localization (arrowheads, n=3 biological replicates). 428 
(g) FACS gating for sorting human AQP5+ and AQP5- cells (means±SEM; n=4 biological 429 
replicates). 430 
(h) Relative AQP5 expression (qPCR) in FACS-sorted AQP5+ and AQP5- cells (n=3 biological 431 
replicates). 432 
(i-j) Outgrowth efficiency of single AQP5+ and AQP5- cells in vitro (i) with representative image 433 
(j) (n=3 biological replicates). 434 
(k-l) Relative LGR5 (k) and MUC5AC (l) expression in (qPCR) AQP5+ cell-derived organoids 435 
on day 4 of differentiation (n=3 biological replicates). 436 
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(m) Heatmap of 200 genes with highest variation between normal human pylorus AQP5+ and 437 
AQP5- populations by RNASEQ (n=8 biological replicates). 438 
(n) GO terms associated with genes significantly enriched in AQP5+ population. 439 
Scale bars represent 100µm in (a),(b),(e),(j) and 50µm in (c),(d),(f). Graphs are presented as 440 
means± s.e.m.; two-sided t-test. 441 
 442 
Fig. 4: Aqp5+ population is a source of Wnt-driven, invasive gastric cancer 443 
(a) Characteristics of gastric cancer models.  444 
(b-h) Characterization of Aqp5-EGFP-IRES-CreERT2;APK intramucosal gastric 445 
adenocarcinoma. H&E stain of entire pyloric region (b) and tumour (green box) (c). 446 
Immunostaining of the tumour region in (b) for Aqp5-GFP (d), E-cadherin (e), phospho-AKT 447 
(f), MAPK (g) and b-catenin (h) in the tumour region (b). (h) is a higher magnification of 448 
Extended Data Fig. 12a.  449 
(i-o) Characterization of Slc9a3-2A-CreERT2;AP gastric adenocarcinoma. H&E of entire 450 
pyloric region (i) and the focal invasion (j). Immunostaining for Aqp5 (k), E-cadherin (l), 451 
phospho-AKT (m), MAPK (n) and b-catenin (o) in the focal invasion. 452 
(p) Co-staining of Aqp5-GPF, Ki67 and E-cadherin in Aqp5-CreERT2;APK pyloric tumour. 453 
(s-u) Organoid assay with Aqp5-GFP+ GFP- tumour cells (n=3 biological replicates). (q) 454 
Initiation frequencies of Aqp5-GFP+ tumour cells (APK-GFP+) versus Aqp5-GFP- tumour cells 455 
(APK-GFP-). Paired two-sided t-test, means±s.e.m. (r) Means and individual longevities of 456 
organoids derived from APK-GFP+, APK-GFP- and Norm-GFP+ (Aqp5-GFP+ cells from 457 
normal pylorus) cells seeded with exogenous growth factors (GF) for a week and without GF 458 
for the next 4 weeks. (s) Representative images of organoids derived from APK-GFP+ cells 459 
and Norm-GFP+ cells in the respective GF conditions.  460 






For exon 1-knockins, an EGFP-IRES-CreERT2 cassette was inserted immediately 465 
downstream of the start codons of Aqp5, A4gnt, Spp1 and Slc9a3 gene loci by homologous 466 
recombination in embryonic stem cells as illustrated in Extended Data Fig. 3a. For 3’ UTR-467 
knockins, a 2A-CreERT2, 2A-EGFP or 2A-DTR cassette was inserted immediately before the 468 
stop codon of Aqp5, Lgr5 and/or Slc9a3 gene loci by homologous recombination in embryonic 469 
stem cells as illustrated in Extended Data Fig. 3b, thereby preserving the intact protein-coding 470 
region and endogenous expression of the genes. Rosa26-tdTomatoLSL (Ai14) (JAX ID 007914) 471 
mice38 were obtained from Jackson Labs. Lgr5-EGFP-IRES-CreERT24 (JAX ID 008875), 472 
Lgr5-DTR-EGFP (MGI ID 5294798)5, KrasLSL-G12D (JAX ID 019104)39, APCfl/fl (MGI ID 473 
1857966)40 and PTENfl/fl (MGI ID 2182005)41 mice have been described previously. All Cre and 474 
EGFP lines are bred as heterozygotes except A4gnt-IRES-CreERT2 and Spp1-IRES-475 
CreERT2 mice, which are bred as homozygotes. All animal experiments were approved by 476 
the “Institutional Animal Care and Use Committee” of Singapore and performed in compliance 477 
with all relevant ethical regulations. Maximum tumour size allowed by IACUC is 20mm in any 478 
dimension and none of the experiments exceeded this limit. For all experiments, adult animals 479 
(not selected for gender) with a minimum age of 7-8 weeks were used. The experiments were 480 
not randomized, and there was no blinded allocation during experiments and outcome 481 
assessment. No statistical method was used to pre-determine sample size. Genotyping 482 
primers are collated in Supplementary Table 4. Mouse lines are available upon request.  483 
Human material 484 
Normal human pylorus for FACS was provided by K.G. Yeoh, J. So and A. Shabbir, NUS 485 
Department of Medicine and Pathology (granted under protocol 11-167E) and N. Inaki and T. 486 
Tsuji, Ishikawa Prefectural Central Hospital. Informed consent was obtained from all patients 487 
and experiments were performed in compliance with all relevant ethical regulations. Human 488 
distal cancer FFPE sections were provided by NUS Department of Medicine and Pathology 489 
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(granted under protocol-11-167E) and Leeds Teaching Hospitals NHS Trust, Leeds, UK 490 
(granted under protocol CA01_122). 491 
Animal treatment 492 
Mice were each injected with tamoxifen dissolved in sunflower oil intraperitoneally at 4 mg 493 
tamoxifen/30g body weight. Diphtheria Toxin (DT)-treated mice were injected with a single 494 
dose of DT dissolved in PBS intraperitoneally at 0.5 ug DT/30g body weight.  495 
Gland isolation, cell dissociation and flow cytometry 496 
Murine pylorus 497 
Murine pylorus was incubated in chelation buffer (5.6 mM sodium phosphate, 8 mM potassium 498 
phosphate, 96.2 mM sodium chloride, 1.6 mM potassium chloride, 43.4 mM sucrose, 54.9 mM 499 
D-sorbitol, 1 mM dithiothreitol) with 5 mM EDTA at 4oC for 2 hours. Glands were isolated by 500 
repeated pipetting of finely chopped pylorus tissue in cold chelation buffer. Chelation buffer 501 
containing isolated glands was filtered through 100 μm filter mesh, and centrifuged at 720g at 502 
4oC for 3 min. The pellet was resuspended in TrypLE (Life Technologies) with DNaseI 503 
(0.8U/μL) (Sigma) and incubated at 37oC for 10 min with intermittent trituration for digestion 504 
into single cells. Digestion was quenched by dilution with cold HBSS buffer. The suspension 505 
was centrifuged at 720g at 4oC for 3 min. For anti-Aqp5 antibody stain, the pellet was 506 
resuspended in HBSS with 2% fetal bovine serum (FBS, Hyclone) with anti-Aqp5-AF647 507 
(Abcam, ab215225) at 1:500 dilution and incubated on ice at 30min in the dark. The pellet was 508 
subsequently washed twice with cold HBSS and spun at 800g for 3min at 4oC. The pellet was 509 
resuspended in HBSS with 2% FBS. Before sorting, 1 μg/ml propidium iodide (Life 510 
Technologies) was added to the cell suspensions, filtered through a 40μm strainer, and sorted 511 
on BD Influx Cell Sorter (BD Biosciences). Cells were collected in RLT Plus buffer (Qiagen) 512 





Human pylorus 516 
Human pylorus was collected in Advanced DMEM/F-12 media with 10 mM HEPES, 2 mM 517 
Glutamax (incubation buffer, all from Life Technologies), supplemented with 1X Anti-Anti (Life 518 
Technologies) and 1mM N-acetylcysteine (Sigma). After at least three washes in HBSS, the 519 
pylorus was finely chopped and digested in incubation buffer supplemented with 1mg/mL 520 
Collagenase (Gibco) and 2mg/mL Bovine Serum Albumin (Sigma) for 30 min at 37oC with 521 
intermittent mixing. The remainder of the processing protocol is identical to that for the murine 522 
tissue described earlier. Cells for organoid culture were collected in organoid culture medium 523 
with growth factors and 0.2% Growth factor-reduced Matrigel (Corning) (v/v). 524 
Organoid culture 525 
Organoid culture of FACS-isolated single human and murine pylorus cells were performed as 526 
described previously42. Briefly, single cells were resuspended in growth factor-reduced 527 
Matrigel (Corning) and cultured in basal media [Advanced DMEM/F-12 media with 10mM 528 
HEPES, 2mM Glutamax, 1X N2, 1X B27 (all Invitrogen), N-acetyl-cysteine (Sigma), Primocin 529 
(Invivogen)] supplemented with these growth factors - EGF (Invitrogen), Gastrin (Sigma), 530 
FGF10 (Peprotech), Noggin (Peprotech), Wnt3a (Millipore), R-spondin and ROCK inhibitor 531 
Y27632 (Sigma). A83-01 (Tocris) is also added to human pyloric cultures. Mouse cancer 532 
organoids were grown in only basal media after first week of culture. Organoids were 533 
passaged when confluent, at least once a week. Only organoids beyond 100 µm and 200 µm 534 
in diameter with a clear central lumen are scored as organoids for Fig. 4 and Fig. 5 535 
respectively. 536 
RNA isolation and qPCR 537 
Tissues were lysed in Trizol (Qiagen) and single cells were lysed in RLT Plus buffer (Qiagen). 538 
RNA was subsequently isolated with RNeasy Universal Plus kit (Qiagen) and cDNA was 539 
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generated with Superscript III (Life Technologies) according to manufacturer's instructions. 540 
qPCR was performed with a minimum of three biological replicates per gene using SYBR 541 
Green dye (Promega) according to the manufacturer's instructions and ran on StepOne or 542 
Quantstudio7 qPCR machines (Applied Biosystems). Analysis was carried out using double 543 
CT method on Step One Software on the respective qPCR machines (Applied Biosystems). 544 
qPCR validation of top candidates from RNASEQ was performed on 2-4 ng of SPIA-amplified 545 
cDNA derived from the Ovation Pico WTA system (Nugen Technologies) due to limitation of 546 
RNA availability. In the event any of the samples for a specific target does not amplify, the 547 
relative expression values of all the samples for that target are increased by one to allow 548 
visualization of the values on a log scale. Sequences of qPCR primers are collated in 549 
Supplementary Table 4. 550 
Transcriptome profiling and analysis 551 
Single cell RNAseq CEL-Seq and RaceID 552 
Single Lgr5-EGFPHi pyloric epithelial cells from Lgr5-DTR-EGFP mice5 were isolated by FACS 553 
(as described earlier) and collected in each well of 96-well plates. Total RNA extracted from 554 
each cell was used to generate single-cell RNA expression libraries as described48. A total of 555 
285 Lgr5-EGFPHi cells from three mice were sequenced on Illumina HighSeq 2500 instrument 556 
using 101 base-pair paired end sequencing. K-means clustering in RaceID was used to 557 
delineate clusters of subpopulations as previously described20. 558 
Microarray and analysis 559 
Labelling, hybridization and washing protocols for microarrays were performed according to 560 
Origene instructions. RNA quality was first determined by assessing the integrity of the 28s 561 
and 18s ribosomal RNA bands on Agilent RNA 60000 Pico LabChips in an Agilent 2100 562 
Bioanalyser (Agilent Technologies). A minimum of 2ng of RNA was used to generate SPIA-563 
amplified cDNA using the Ovation Pico WTA system (Nugen Technologies). Five micrograms 564 
of SPIA-amplified purified cDNA was then fragmented and biotin-labelled using the Nugen 565 
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Encore Biotin module (Nugen Technologies). Microarray was performed using the Affymetrix 566 
Mouse ST v2.0 GeneChips (Affymetrix), which consists of more than 28,000 probes for 567 
previously annotated genes. The individual microarrays were washed and stained in an 568 
Affymetrix Fluidics Station 450, and hybridized probe fluorescence was detected using the 569 
Affymetrix G3000 GeneArray Scanner. Image analysis was carried out on the Affymetrix 570 
GeneChip Command Console v2.0 using the MAS5 algorithm. CEL files were generated for 571 
each array and used for gene expression analysis. The CEL files were then processed in R 572 
(v3.2.3) with the Bioconductor (v3.2) libraries ‘oligo’ (v1.34.2), ‘pd.mogene.2.0.st’ (v3.14.1) 573 
and ‘limma’ (v3.26.8). We used Robust Multi-array Average (RMA) to perform background 574 
correction and normalization with the ‘rma’ function implemented in the ‘oligo’ package (‘target’ 575 
parameter was set to ‘core’ to obtain expression values at the gene level). The experimental 576 
design was stored as a single factor with individual levels for each combination of Lgr5-GFP 577 
level (high, low, negative) or Aqp5 status (positive, negative). Linear models were fitted to the 578 
expression data with the function ‘lmFit’ (default parameters). The relevant contrasts were 579 
fitted with ‘contrasts.fit’ (default parameters); differential expression was tested with ‘eBayes’ 580 
(default parameters). Differential gene expression was analyzed using Partek Genomics Suite 581 
software (Partek). Relative gene expressions are depicted as single values as given by Partek 582 
Analysis Software. Gene Set Enrichment Analysis was performed using the GSEA v6.146,47. 583 
RNASEQ 584 
AQP5+ and AQP5- cells were collected directly into RLT Plus buffer by FACS sorting. Total 585 
RNA was isolated using Qiagen RNeasy Micro Kit (QIAGEN). RNA quality was first 586 
determined by assessing the integrity of the 28s and 18s ribosomal RNA bands on Agilent 587 
RNA 60000 Pico LabChips in an Agilent 2100 Bioanalyser (Agilent Technologies). Amplified 588 
cDNA library was prepared according to manufacturer’s instructions with SMARTer Stranded 589 
Total RNA-Seq Kit v2 - Pico Input Mammalian (Takara) using 10ng of input Total RNA. 590 
Indexed 150bp paired end sequencing was performed on HiSeq 2500 (Illumina) and Illumina 591 
Real-Time Analysis (RTA) software was used for base-calling to generate Fastq files. The 592 
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reads were mapped to Genome Reference Consortium Human Build 38 patch release 12 593 
(GRCh38.p12) with STAR software version 2.5.3a with the following options issued: --594 
outFilterType BySJout, --outFilterMultimapNmax 10, --alignSJoverhangMin 15, --595 
alignSJDBoverhangMin 1, --outFilterMismatchNmax 12, --outFilterMatchNminOverLread 0.4, 596 
--alignIntronMin 20, --alignIntronMax 2000000, --outSAMattrIHstart 0, --outSAMmapqUnique 597 
244, --outMultimapperOrder Random, --outReadsUnmapped None, --outFilterIntronMotifs 598 
None, --outSAMmode Full, --outSAMattributes All --quantMode GeneCounts, --599 
clip3pAdapterSeq 600 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT. 601 
Counts per sample were subsequently concatenated in a statistical software, R version 3.2.3, 602 
and reads were normalized with Trimmed mean of M values (TMM) normalisation as 603 
implemented in edgeR version 3.12.1 (with limma_3.26.9). Differential expression testing was 604 
performed with the edgeR function “glmQLFit” using a design matrix that took sample batches 605 
and AQP5 status into account. Differentially expressed genes (DEGs) were those with more 606 
than 2-fold change between AQP5+ and AQP5- samples, with FDR<0.05. Due to likely 607 
inclusion of immune cells in the profile, immune-related genes43 were omitted,  resulting in a 608 
final list of >500 DEGs. Gene Ontology, Overrepresentation Analysis (ORA) and PANTHER 609 
Pathway analysis of the DEGs were performed on the PANTHER Classification System44 610 
using default parameters. 611 
Transcriptomic pathway signature analysis of human gastric cancer 612 
Level 3 TCGA RNA-seq normalized matrix for 415 GC and 35 normal gastric samples and 613 
their corresponding clinical information were downloaded from the Broad Institute TCGA 614 
Genome Data Analysis Center (GDAC) Firehose (https://gdac.broadinstitute.org/). Gene 615 
expression data of 200 GC and 100 matched normal gastric samples were generated using 616 
Affymetrix Human Genome U133 Plus 2.0 Array (GSE15459) and processed as described 617 
previously16. All normal samples and only tumours of antral or pyloric origin were included for 618 
analysis. To determine activity of PI3K, Wnt and KRAS pathways in primary tumours, we 619 
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utilized published pathway signatures by several groups: KRAS signature based on differential 620 
gene expression analysis between high KRAS mutation and low KRAS mutation/wildtype CRC 621 
tumours18; PI3K signature composed of genes modulated in vitro by PI3K inhibitors, according 622 
to the CMap signature17 and lastly, intestinal Wnt signature defined by profiling CRC cell lines 623 
carrying an inducible block of the Wnt pathway and differential gene expression analysis of 624 
human colon adenoma and adenocarcinomas versus normal colonic epithelium19. For each 625 
pathway signature, only up-regulated genes in pathway activation were selected for 626 
downstream analysis. 627 
To quantify the relative activation level in a specific oncogenic pathway, we derived a “µ score” 628 
for each sample profile. In brief, the transcriptomic “µ score” was defined as the average of 629 
standardized expression values of those up-regulated genes in a specific oncogenic pathway 630 
(after the log-transformed values centred to the standard deviation from the median across 631 
the samples included in the analysis). For each oncogenic pathway, “µ scores” were 632 
calculated for all normal samples, and the “µ score” at the 90% percentile of the normal 633 
samples was used as the cut-off to define a pathway as “hyperactivated”.  The “µ score” for 634 
each tumour was determined and a “µ score” higher than the cut-off was considered to be 635 
“hyperactivated” for that particular pathway. For each combination of pathways (Wnt, 636 
Wnt/PI3K or Wnt/PI3K/Kras), the concurrence rate was given by the frequency of tumours that 637 
were “hyperactivated” in all the pathways in question. 638 
Histology 639 
Immunohistochemistry (IHC) and immunofluorescence (IF). 640 
IHC and IF were performed according to standard protocols. In summary, tissues were fixed 641 
in 4% paraformaldehyde/PBS (w/v) overnight at 4oC, and processed into paraffin blocks. 8 µm 642 
sections from the paraffin blocks and tissue microarray slides were deparaffinated and 643 
rehydrated, followed by antigen retrieval via heating to 121oC in a pressure cooker in standard 644 
10mM citric acid pH6 buffer, a commercial citrate pH 6.1 buffer (S1699, DAKO) or Tris/EDTA 645 
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buffer, pH 9.0 (S2367, DAKO). Primary antibodies used were chicken anti-EGFP (1:2,000, 646 
Abcam, ab290), rabbit anti-EGFP (1:200; Cell Signalling, 2956S), rabbit anti-Ki67 (1:200; 647 
Thermofisher, MA5-14520), rabbit anti-GIF (1:10,000; provided by D. H. Alpers, Washington 648 
University School of Medicine, USA), rabbit anti-RFP (1:200; Rockland, 600-401-379), rabbit 649 
anti-aquaporin5 (1:200, Santa Cruz, SC-28628 and 1:500, LSBio, LS-C756566), rabbit anti-650 
Slc9a3 (1:200; Santa Cruz, SC-16103-R), rabbit anti-mucin6 (1:200; LsBio, LS-C312108), 651 
rabbit anti-A4gnt (1:500, Novus Biologicals, NBP1-89129), rabbit anti-Gastrin (1:200, Leica 652 
Biosystems, NCL-GASp), mouse anti-MUC5AC (1:200; Leica Biosystems, NCL-HGM-45-M1), 653 
rabbit anti-vimentin (1:500; Abcam, ab92547), mouse anti-E-cadherin (1:200; BD 654 
Transduction Laboratories, 610181), mouse anti-β-catenin (1:200; BD Transduction 655 
Laboratories, 610154), mouse anti-RFP (1:200; Abcam, 129244), mouse anti-ChgA (1:200; 656 
Abcam, 15160), rabbit anti-Phospho-MAPK (1:200; Cell Signalling, 4370S), mouse anti-H-K-657 
ATPase (1:1,000; MBL International Corporation, D032-3), rabbit anti-Phospho-Akt (1:200; 658 
Cell Signalling, 3787L). Detailed information about clone number, and antibody validation is 659 
found in Supplementary Table 6. The peroxidase-conjugated secondary antibodies used were 660 
mouse/rabbit EnVision+ (DAKO) for HRP IHC or anti-chicken/rabbit/mouse Alexa 661 
488/568/647 IgG (1:500; Invitrogen) for IF. GSII-Lectin-AF568 (1:500, Thermofisher) was 662 
incubated on the slides for 1 hour at RT together with secondary antibodies. IHC sections 663 
were dehydrated, cleared, and mounted with DPX (Sigma) while IF sections were mounted in 664 
Hydromount (National Diagnostics) with Hoechst for nuclear staining. Immunostainings and 665 
imaging were performed on a minimum of three biological replicates and representative 666 
images of the replicates were included in the manuscript. 667 
Haematoxylin and eosin (H&E). 668 
H&E staining was performed on FFPE sections according to standard laboratory protocols. 669 
Whole mount analysis and vibratome sectioning 670 
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Tissues were fixed in 4% paraformaldehyde/PBS (w/v) overnight at 4oC. Whole mount tissues 671 
were permeabilized in 2% TritonX-100/PBS (v/v) overnight at 4oC, while 500 µm vibratome 672 
sections were generated by sectioning tissues embedded in 4% low-melting point agarose 673 
with a vibrating microtome (Leica) and permeabilized in 2% TritonX-100/PBS (v/v) overnight 674 
at 4oC. Rapiclear (Sunjin lab) was used to clear whole mount tissues and vibratome sections 675 
according to manufacturer's instructions. Hoescht was used as nuclear counterstain. 676 
In situ hybridization (ISH) 677 
ISH and co-ISH was performed using RNAscope45 2.5 High Definition Brown Assay and 2.5 678 
High Definition Duplex Reagent Assay (Advanced Cell Diagnostics) respectively, according to 679 
manufacturer's instructions. DapB was used as negative control for all the RNAscope 680 
experiments. In situ hybridization and imaging were performed on a minimum of three 681 
biological replicates and representative images of the replicates were included in the 682 
manuscript. 683 
Analysis and scoring of stainings on mouse and human FFPE sections 684 
Overlap of Slc9a3-GFP and Aqp5-antibody stains was determined by counting stained cells 685 
contacting the lumen at the base of glands. The entire height of the gland base surrounding 686 
the gland base lumen had to be visible to avoid over-or underrepresentation of localized 687 
populations.  688 
Samples of H&E sections of mouse gastric tumours were evaluated by qualified veterinary 689 
and clinical histopathologists.  Scoring of AQP5 staining on human gastric cancer specimens 690 
was performed by qualified clinical histopathologists. The tumour in the tissue section was 691 
considered positive for AQP5 if staining was observed in more than 5% of the malignant cells. 692 
Subcellular localization of AQP5, relative staining intensities and stained features were all 693 
determined by qualified pathologists. 694 
Microscopy imaging 695 
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Image acquisition 696 
IHC and H&E slides were imaged with Zeiss AxioImager Z1 Upright microscope. RNAscope 697 
slides and large area images were captured with Nikon Ni-E microscope/DS-Ri2 camera. IF 698 
slides were imaged using Olympus FV1000 and FV3000 confocal microscopes. Cultured 699 
organoids were imaged with Olympus DP-27 camera on Olympus IX53 inverted microscope. 700 
Image processing 701 
RNAscope and images with large areas were processed with NIS-Elements AR software 702 
(Nikon) with EDF and stitching features respectively. IF images were processed using ImageJ 703 
(NIH) and whole mount organoid images were processed using Imaris 8.0 (Bitplane). 704 
Statistics and reproducibility 705 
Gene expression data were quantified and depicted as the mean±SEM. Statistical analyses 706 
were performed using GraphPad Prism. Data were tested for statistical significance by paired 707 
two-tailed t-test unless otherwise stated in figure legends. Statistical significance of overlap 708 
between the two gene sets in Fig. 1b was determined by hypergeometric distribution 709 
(http://nemates.org/MA/progs/overlap_stats.html). Precise P values of statistical significance 710 
are shown in the respective figures. Representative images of all histological experiments and 711 
FACS sorting strategies were performed at least thrice independently with similar results,  712 
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Extended Data Figure Legends 795 
Extended Data Fig. 1 796 
(a-c) FACS sorting strategy sorting GFPhi and GFPlo cells from Lgr5-EGFP-IRES-CreERT2 797 
pylorus (a), small intestine (b) and colon (c). 798 
(d) Lgr5 expression (qPCR) in sorted populations and unsorted tissues of the gastrointestinal 799 
tract data represented as means± s.e.m. (n=4 biological replicates); one-way ANOVA test. 800 
(e) Aqp5 protein expression in the mouse stomach through to the duodenum by 801 
immunostaining (n=3 biological replicates). 802 
(f-i) Aqp5 mRNA expression in the corpus (f), Brunner’s glands (g), small intestine (h) and 803 
colon (i) by ISH (n=3 biological replicates).  804 
(j-n) A4gnt (j), GIF (k), Muc6 (l), Slc9a3 (m) and Spp1 (n) expression in the corpus, Brunner’s 805 
glands, small intestine and colon by qPCR, ISH, and co-ISH with Lgr5. For histology 806 
experiments, n=3; For qPCR, n=4 biological replicates for GIF, Muc6 and Slc9a3 qPCRs 807 
where data is represented as means± s.e.m., n=2 technical replicates from a pooled sample 808 
of 8 for A4gnt and Spp1 qPCRs. 809 
Scale bars represent 500 µm in (e), and 20 µm in (f-n). 810 
 811 
Extended Data Fig. 2 812 
(a) Exon1-knockin gene strategy to generate EGFP-CreERT2 reporters of Aqp5, A4gnt, 813 
Slc9a3 and Spp1 expression. 814 
(b) 3’UTR-knockin gene strategy to generate 2A-EGFP, 2A-CreERT2 or 2A-DTR reporters of 815 
Aqp5, Slc9a3 and Lgr5 expression. 816 
(c-f) GFP signal in the pylorus and small intestine of Aqp5-2A-EGFP (c-d) and Slc9a3-2A-817 
EGFP mice (e-f). 818 
(g-h) Quantification of the overlap between Slc9a3-2A-EGFP+ cells and Aqp5+ cells (g) 819 
(n=102 glands from three mice) and a representative image of the immunostaining (h). Results 820 
are presented as means±s.e.m. 821 
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(i-j) Quantification of overlap between Lgr5-EGFP+ cells with Aqp5+ cells (i) (n=117 glands 822 
from four mice) and a representative image of the immunostaining (j). Results are presented 823 
as means±s.e.m. 824 
(k-m) Co-localization of Lgr5-EGFP in the pylorus with GIF (k), Gastrin (l) and Chromogranin 825 
A (m) (n=3 biological replicates).  826 
(n) t-SNE map of single Lgr5Hi cells from the pylorus (n=285 cells from three mice). 827 
(o-s) t-SNE maps showing enrichment of candidate markers in major (o-q) and minor (r-s) 828 
subpopulations of Lgr5Hi pyloric cells (n=285 cells from 3 mice). 829 
(t) Frequency of 10 published proliferation markers (Bcl2, Ccnd1, Ckap2, Foxm1, Ki67, Mcm2, 830 
Mybl2, Plk1, Rrm2, Top2a) in major versus minor subpopulations, compared by two-tailed 831 
Mann-Whitney test (n=285 cells from 3 mice, 248 cells in major, 8 cells in minor 1 and 1 cells 832 
in minor 2 populations).  833 
(u-v) Aqp5 (u) and Lgr5 (v) expression in cells sorted from Aqp5-EGFP-IRES-CreERT2 pylori 834 
(means±s.e.m.; n= 4 biological replicates).  835 
(w-x) Co-immunostaining for EGFP driven by Aqp5-EGFP-IRES-CreERT2 and endogenous 836 
Aqp5 (w) and Ki67 (x) (n=3 mice).  837 
Scale bars represent 50 µm in (g),(h) and 25 µm in (k),(m),(w),(x). 838 
 839 
Extended Data Fig. 3 840 
(a-p) Lineage tracing in A4gnt-, Aqp5-, Spp1- and Slc9a3-EGFP-IRES-CreERT2 mice crossed 841 
with tdTomatoLSL reporter mice after short trace (20-48 hours) in the pylorus (a-d) and small 842 
intestine (i-l) and long trace (>3 months) in the pylorus (e-h) and small intestine (m-p) (n=3 per 843 
genotype). 844 
(q-x) Lineage tracing in pylorus (q-t) and small intestine (u-x) of the Aqp5-2A-CreERT2 and 845 
Slc9a3-2A-CreERT2 mice after short trace (q-r, u-v) and long trace (s-t, w-x).  846 
(y-b’) Whole-mount imaging of pylorus from induced Aqp5-EGFP-IRES-CreERT2;tdTomatoLSL 847 
mice 20 hours (y) and 6 months (z) after induction. Whole-mount imaging of pylorus from 848 
uninduced 8 week-old (a’) and 8 month-old (b’) Aqp5-EGFP-IRES-CreERT2;tdTomatoLSL mice 849 
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(n=3 per condition). dTom signal through the entire height of the pyloric epithelium is shown 850 
and DAPI from the upper parts of pyloric glands is depicted for clarity. 851 
(c’-e’) dTom signal in clusters of glands in 1 year-traced pylorus (c’) and small intestine (d’-e’). 852 
(f’-h’) dTom expression in gastric corpus (f’), colon (g’) and brunner’s glands (h’) 20 h and 6 853 
months after induction. 854 
N=3 biological replicates. Scale bars represent 50 µm.  855 
 856 
Extended Data Fig. 4 857 
(a) Aqp5+ gating strategy with cells from WT pylorus stained only with propidium iodide. 858 
(b) Heatmap of transcriptomes from Aqp5+ and Aqp5- cells (n=4 biological replicates). 859 
(c) GSEA analysis comparing degree of overlap between transcriptomes of Aqp5+ cells and 860 
Lgr5+ cells from the pylorus using Kolmogorov-Smirnov statistic (n=4 biological replicates 861 
each). 862 
(d-e) Relative Aqp5 (d) and Lgr5 (e) expression (from microarray) in Aqp5+ and Aqp5- cells 863 
(n=4 biological replicates) by one-way ANOVA in Partek suite.  864 
(f-h) Relative expression of various pyloric markers (f), other published pyloric stem cell 865 
markers (g) and lineage and proliferation markers (h) in Aqp5+ population versus Aqp5- 866 
population in microarray (n=4 biological replicates). Data represented as means, as derived 867 
from Partek Analysis Software by one-way ANOVA. 868 
(i-j) Aqp5 staining in a whole-mount organoid (i) and Aqp5 co-localization with Ki67 (j) in an 869 
organoid section. Organoids were derived from single Aqp5+ cells (n=3 biological replicates).  870 
(k-r) Pylori of DT-treated WT (k-n) and Aqp5-2A-DTR (o-r) mice stained for H&E (k, o), E-871 
Cadherin (l, p), Gif (m, q) and Gastrin (n, r) (n=3 biological replicates).  872 
(s-u) Outgrowth efficiency of Aqp5+, Aqp5-, Lgr5-EGFP+, Lgr5-EGFP- cells (s) (n=5 biological 873 
replicates for Aqp5+/- cells, n=3 biological replicates for Lgr5-EGFP+/- cells). Representative 874 
images of organoids derived from Lgr5-EGFP+ (t) and Lgr5-EGFP- (u) cells. Paired two-sided 875 
t-test. 876 




Extended Data Fig. 5 879 
(a-f’) MUC6 (a-b’), A4GNT (c-d’) and SLC9A3 (e-f’) expression (co-ISH with LGR5 and 880 
immunostaining) in normal human pylorus (n=3 biological replicates).  881 
(g-j) Co-ISH to co-localize AQP5 with PEPC (g), MUC6 (h), GIF (i) and MUC5AC (j) pyloric 882 
lineage markers (n=3 biological replicates). 883 
(k-l) AQP5 labelling in whole mount human organoids (k) and AQP5 colocalization with KI67 884 
(l) in organoid sections (n=3 biological replicates).  885 
(m-o) Relative AXIN2 (m), TFF2 (n) and AQP5 (o) expression in AQP5+ cell-derived organoids 886 
3 days after WNT3A, Noggin and FGF10 withdrawal by qPCR (n=3 biological replicates). 887 
Scale bars represent 100 µm in all panels except (a’), (b’), (c’), (d’), (e’), (f’), (k) where they 888 
represent 25 µm. 889 
 890 
Extended Data Fig. 6 891 
(a-e) qPCR validation (green, n=5 biological replicates) and RNASEQ values (blue, n=8 892 
biological replicates) of murine stem cell markers (a), membrane components (b), chemokine 893 
signaling components (c), extracellular matrix components (d) and other genes (e). Two-sided 894 
Mann-Whitney test was used to determine statistical significance of qPCR results differences 895 
for all genes except AQP5, which was determined by two-tail paired t-test. qPCR and 896 
RNASEQ results are presented as means. 897 
(f-f”) ISH of SMOC2 (brown) on normal human pylorus. (f’) is magnified inset of surface 898 
mucosa, while (f”) is magnified inset of gland base (n=4 biological replicates). Scale bars 899 
represent 100 µm in (f), and 10 µm in (f’) and (f”). 900 
(g) Top 10 Panther pathways enriched with most candidate genes. 901 
 902 
Extended Data Fig. 7 903 
(a-b) Co-hyperactivation status of the Wnt, PI3K and Kras pathways in human distal gastric 904 
cancer samples from TCGA3 (a) (n=155) and GSE1545916 (b) (n=42) datasets. Heatmaps 905 
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show distribution of pathway hyperactivation statuses across samples. Graphs depict 906 
distribution of µ-scores (degree of signalling activity) of normal and tumour samples for each 907 
of the pathways examined. 908 
 909 
Extended Data Fig. 8 910 
(a) Sample sizes, tumour and invasion incidences observed in various permutations of 911 
CreERT2 drivers and oncogenic alleles. 912 
(b-g) Whole mount and H&E images of entire pyloric regions for each CreERT2-oncogenic 913 
allele combination. 914 
(h-l) H&E images of pylori from multiple pyloric marker-CreERT2;KrasLSL-G12D models (h-i), 915 
APK-only model (without CreERT2 driver) (j), and small intestine (k) and colon (l) from Aqp5-916 
IRES-CreERT2;APK gastric cancer mouse model. 917 
Scale bars represent 1 cm in whole mount insets in (b-g), 200 µm in H&E images in (b-l).  918 
 919 
Extended Data Fig. 9 920 
(a-g) Immunostaining of various markers in Aqp5-IRES-CreERT2;APK pyloric tumour. 921 
(h-h”) Co-ISH of Aqp5 and Lgr5 in tumour region, magnified in (h’). Dual ISH of Aqp5 and Lgr5 922 
in an adjacent normal pyloric region from the same mouse (h”). 923 
(i-i’) Representative H&E stain of a salivary gland tumour from Aqp5-IRES-CreERT2;APK 924 
mouse. 925 
(j-o) Immunostaining of various markers in Slc9a3-2A-CreERT2;AP pyloric tumour. 926 
(p-w) Immunostaining of various markers in the APK-only (no CreERT2) control pyloric 927 
stomach. 928 
(x-x’) Colocalization of Aqp5-EGFP and endogenous Aqp5 protein in pyloric tumour from an 929 
Aqp5-IRES-CreERT2;APK mouse. 930 
(y-z) Control FACS gating for GFP+ cells using normal Aqp5-EGFP-IRES-CreERT2 (y) and 931 
WT (z) pylori (n=3 biological replicates). 932 
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(y-z”) Organoid assay for stemness of Aqp5-GFP+ tumour cells (n=3 biological replicates). (y) 933 
Experimental timeline. FACS gating strategy to isolate GFP+ tumour cells from Aqp5-934 
CreERT2;APK pyloric tumour (z), GFP+ cells from normal Aqp5-EGFP-IRES-CreERT2 935 
pylorus (z’), and control GFP gating with WT pylorus (z”). 936 
Scale bars represent 100 µm in (a-g and i-x’), 100 µm in (h’), 20 µm in (h”). 937 
Extended Data Fig. 10 938 
(a) Summary of AQP5 expression in a tumour microarray panel of 145 cores of human distal 939 
gastric cancer. AQP5 expression is scored as positive if observed in > 5% malignant cells.  940 
(b-e) Examples of AQP5+ cores with intestinal (b-c) and diffuse (d-e) subtypes, often with 941 
cytoplasmic and/or membranous staining.  942 
(f) Summary of AQP5 expression from 54 full sections of distal human gastric cancer.  943 
(g-n) AQP5 expression in intestinal (g),(h),(k),(l) and diffuse (I),(j),(m),(n) subtypes. Yellow 944 
arrowheads indicate cells co-expressing AQP5 and KI67.  945 
(o) Summary of other observations of AQP5 expression in full gastric tumour sections.  946 
(p-s) AQP5 expression in the invasive edge of the tumour (p), intestinal metaplasia (IM) (q, 947 
dotted lines denote IM region negative for AQP5), Signet ring cells (r, black arrows denote 948 
cells with weak AQP5 expression) and tumour cells in lymph node (LN) metastasis (s). 949 
*Mixed refers to AQP5 localization in cytoplasm and nucleus, or cytoplasm and membrane. 950 
Scale bars represent 20 µm in (g-n), (q-r), 50 µm in (b-e), (p), (s).   951 
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Total sample size Tumour incidence Invasion incidence Average survival time
Exon1-IRES-CreERT2 23 19 (82.6%) 3 (15.8%) 6.7 months
3' UTR-2A-CreERT2 12 12 (100%) 8 (66.7%) 3.6 months
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